Inhibitor Therapeutics Incformerly known as HedgePath Pharmaceuticals

INHIBITOR Therapeutics, Inc. is a publicly traded pharmaceutical company based in Tampa, Florida. The company employs three people and generates approximately $2.5 million in annual revenue. INHIBITOR Therapeutics, Inc. is focused on developing and commercializing innovative therapies for patients with cancer and non-cancerous proliferation disorders. Their lead product candidate, SUBA-Itraconazole, is a patented, oral formulation of itraconazole, an FDA-approved anti-fungal drug. INHIBITOR is developing SUBA-Itraconazole for late-stage, metastatic castrate-resistant prostate cancer (mCRPC) and late-stage non-squamous non-small cell lung cancer (NSCLC). The company holds exclusive rights to SUBA-Itraconazole for the treatment of certain cancers and non-cancerous proliferation disorders in the United States. INHIBITOR's lead programs benefit from SUBA-Itraconazole's prior FDA approval, which provides a 505(b)(2) pathway, ensuring proven bioavailability, safety, and anti-tumor efficacy. A previous clinical trial conducted by INHIBITOR demonstrated the effectiveness of SUBA-Itraconazole in treating 38 patients with Basal Cell Carcinoma Nevus Syndrome (BCCNS). A Phase 2b trial in BCCNS confirmed the low toxicity safety profile of SUBA-Itraconazole compared to other oncology drugs targeting the same pathway for treating basal cell carcinoma lesions. INHIBITOR Therapeutics, Inc. can be reached online at inhibitortx.com.